All In Biotech

Drug Trial Radar · NCT02623556

Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen

For Tuberculosis (TB) Clinical Auxiliary Diagnosis of Recombinant Mycobacterium Tuberculosis Allergen ESAT6 - CFP10 Dose of Certain Phase III Clinical Research

Last checked: Nov 19, 2026Latest source record: Apr 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,090 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,090

Planned (sponsor's estimate)

Start

Dec 2015

Primary completion

Mar 2018

Study completion Mar 2018

Sponsor

Sponsor type
Industry
Collaborators
Shanghai Public Health Clinical Center; Tianjin Haihe Hospital; Air Force Military Medical University, China; Proswell Medical Corporation; Wuhan Institute for Tuberculosis Control; Beijing Chest Hospital; Wuxi Hospital for Infectious Diseases; First Affiliated Hospital of Chongqing Medical University; Fuzhou Pulmonary Hospital of Fujian; Zhenjiang Third People's Hospital; Anhui Provincial Hospital; Shenzhen Third People's Hospital
First posted
Dec 7, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

720 cases TB (Tuberculosis patients) participants、360 cases non-TB participants with lung disease and suspected TB patients who all meet the standard are divided into different groups through a randomized and blind method. Every subject inject intradermally ESAT6-CFP10 and TB-PPD (tuberculin purified protein derivative) in different arms of the same person by blind method. Specific gama-interferon (γ-IFN) detection is needed before the injection.Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h. At the same time, we observe all kind of adverse events.

Conditions

  • Tuberculosis

Interventions

  • ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right armBiological

    All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.

  • ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left armBiological

    All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Immune response of left arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in TB patientsTime frame: within 72h after injection
  2. Immune response of right arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in TB patientsTime frame: within 72h after injection
  3. Immune response of left arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in non-TB subjects with lung diseaseTime frame: within 72h after injection
  4. Immune response of right arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in non-TB subjects with lung diseaseTime frame: within 72h after injection

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Wuxi NO.5 People's Hospital

    Wuxi, Jiangsu, China

  • Shanghai Public Health clinical Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.